CervoMed Inc. CRVO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-12.9
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.0M | -$27.0M | — | — | $18.2M |
| 2024 | $9.7M | -$16.3M | — | — | $39.2M |
| 2023 | $7.1M | -$2.2M | — | — | $7.4M |
| 2022 | $0 | -$5.8M | — | — | -$33.3M |
| 2021 | — | -$24.1M | — | — | -$27.9M |
| 2020 | — | -$14.2M | — | — | $24.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| BOGER JOSHUA S | director | 2026-06-11 | Buy | 955,414 | $3.14 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.9 (distress)
- Working capital / assets 0.796
- Retained earnings / assets -4.27
- EBIT / assets -1.237
- Equity / liabilities 3.914
Source: SEC EDGAR filings · CIK 0001053691 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.